In breast cancer cell lines, miR155 has been demonstrated to promote tumour cell growth via altered glucose metabolism, by increasing activity of the phosphoinositide 3-kinases (PI3K)-FOXO3a/c-MYC axis, and reducing glucose transport 4 (GLUT4) expression42. This evidence concerns the gene SLC2A4 and neoplasm.